CLDN6 and ovarian neoplasm: Building from preclinical studies (100), researchers opened a clinical trial evaluating CLDN6 CAR-T +/- CARVac in patients with refractory metastatic CLDN6-positive solid tumors (germ cell and ovarian tumors predominantly), which has reported interim results for 22 of the patients enrolled (103).